Management of acute and chronic migraine

Current Opinion in Supportive and Palliative Care

Volumn 6, Issue 2, 2012, Pages 177-182

  Coppola, Gianluca ^a   Schoenen, Jean ^b  

^a IRCCS FONDAZIONE BIETTI   (Italy)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Acute; Migraine; Preventive; Review; Treatment

Indexed keywords

AZEPINE DERIVATIVE; BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; IMIDAZOLE DERIVATIVE; N (6 (2,3 DIFLUOROPHENYL) 2 OXO 1 (2,2,2 TRIFLUOROETHYL)AZEPAN 3 YL) 4 (2 OXO 2,3 DIHYDRO 1H IMIDAZO(4,5 B)PYRIDIN 1 YL)PIPERIDINE 1 CARBOXAMIDE; N-(6-(2,3-DIFLUOROPHENYL)-2-OXO-1-(2,2,2-TRIFLUOROETHYL)AZEPAN-3-YL)-4-(2-OXO-2,3-DIHYDRO-1H-IMIDAZO(4,5-B)PYRIDIN-1-YL)PIPERIDINE-1-CARBOXAMIDE; TRYPTAMINE DERIVATIVE;

ACUTE DISEASE; CHRONIC DISEASE; DRUG ANTAGONISM; HUMAN; MIGRAINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ACUTE DISEASE; AZEPINES; BOTULINUM TOXINS, TYPE A; CHRONIC DISEASE; HUMANS; IMIDAZOLES; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; TRYPTAMINES;

EID: 84860715051     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e3283521dc3     Document Type: Review

References (37)

1. Magis D, Schoenen J. Treatment of migraine: update on new therapies. Curr Opin Neurol 2011; 24:203-210.
2. Loder E. Triptan therapy in migraine. N Engl J Med 2010; 363:63-70.
3. Cortelli P, Allais G, Tullo V, et al. Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies. Neurol Sci 2011; 32 (Suppl. 1):S95-S98.
4. Tullo V, Allais G, Ferrari MD, et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study. Neurol Sci 2010; 31 (Suppl. 1):S51-S54.
5. Savi L, Omboni S, Lisotto C, et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. J Headache Pain 2011; 12:219-226.
6. Bartolini M, Giamberardino M, Lisotto C, et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. J Headache Pain 2011; 12:361-368.
7. MacGregor EA. Prevention and treatment of menstrual migraine. Drugs 2010; 70:1799-1818.
8. Allais G, Tullo V, Benedetto C, et al. Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurol Sci 2011; 32 (Suppl. 1):S99-S104.
9. MacGregor EA, Pawsey SP, Campbell JC, Hu X. Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: results of a new analysis of data from five previously published studies. Gender Med 2010; 7:88-108.
10. Géraud G, Spierings E, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache 2002; 2:S93-S99. (Pubitemid 34568922)
11. Silberstein S, Elkind A, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004; 63:261-269. (Pubitemid 38971124)
12. MacGregor E, Brandes J, Silberstein S, et al. Safety and tolerability of shortterm preventive frovatriptan: a combined analysis. Headache 2009; 49:1298-1314.
13. Brandes J, Poole A, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia 2009; 29:1133-1148.
14. Cady R, Diamond M, Diamond M, et al. Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache 2011; 51:664-673.
15. Díaz-Insa S, Goadsby P, Zanchin G, et al. The impact of allodynia on the efficacy of almotriptan when given early in migraine: data from the 'act when mild' study. Int J Neurosci 2011; 121:655-661.
16. Goadsby P, Zanchin G, Geraud G, et al. Early vs. nonearly intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 2008; 28:383-391. (Pubitemid 351341454)
17. Tepper S, Kori S, Borland S, et al. Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia. Headache 2012; 52:37-47.
18. Lantéri-Minet M, Mick G, Allaf B. Early dosing and efficacy of triptans in acute migraine treatment: the TEMPO study. Cephalalgia 2012; 32:226-235.
19. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350:1104-1110. (Pubitemid 38298990)
20. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008; 70:1304-1312. (Pubitemid 351550355)
21. Behm M, Blanchard R, Murphy M, et al. Effect of telcagepant on spontaneous ischemia in cardiovascular patients in a randomized study. Headache 2011; 51:954-960.
22. Ho A, Dahlöf C, Silberstein S, et al. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia 2010; 30:1443-1457.
23. Connor K, Aurora S, Loeys T, et al. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache 2011; 51:73-84.
24. Ho T, Olesen J, Dodick D, et al. Antimigraine efficacy of telcagepant based on patient's historical triptan response. Headache 2011; 51:64-72.
25. Ho T, Ferrari M, Dodick D, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008; 372:2115-2123.
26. Hewitt D, Martin V, Lipton R, et al. Randomized controlled study of telcagepant plus Ibuprofen or acetaminophen inmigraine. Headache 2011; 51:533-543.
27. Headache Classification Committee, Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26:742-746.
28. Stovner LJ, Zwart JA, Hagen K, et al. Epidemiology of headache in Europe. Eur J Neurol 2006; 13:333-345.
29. Aurora S, Dodick D, Turkel C, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30:793-803.
30. Diener H, Dodick D, Aurora S, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebocontrolled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30:804-814.
31. Aurora S, Winner P, Freeman M, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-Week PREEMPT clinical program. Headache 2011; 51:1358-1373.
32. Lipton R, Varon S, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 2011; 77:1465-1472.
33. Oterino A, Ramón C, Pascual J. Experience with onabotulinumtoxinA (BO-TOX) in chronic refractory migraine: focus on severe attacks. J Headache Pain 2011; 12:235-238.
34. Christie S, Giammarco R, Gawel M, et al. Botulinum toxin type A and acute drug costs in migraine with triptan overuse. Can J Neurol Sci 2010; 37:588-594.
35. Luo N, Di W, Zhang A, et al. A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Med 2012; 13:80-86.
36. Krymchantowski A, da Cunha Jevoux C, Bigal M. Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders. J Headache Pain 2012; 13:53-59.
37. Krymchantowski A, da Cunha Jevoux C. Low-dose topiramate plus sodium divalproate for positive responders intolerant to full-dose monotherapy. Headache 2012; 52:129-132.